Health

Alexandria Venture Investments was among the participants in a series A round for the cellular cancer therapeutics developer.

Limited partners including Alexandria Venture Investments and Royal Bank of Canada backed the healthcare technology-focused firm's first fund.

11Street and CJ Group contributed to a $71.8m round for on-demand logistics provider Barogo while Eli Lilly helped provide $66m for macrocycle drug developer Circle Pharma.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.

Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.

GV has participated in a $41.9m series B extension for the birth control delivery service, which increased the round's size to $92.9m.

UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.